Zomedica Narrows Losses, Revenue Up 15.9% in Q2

TL;DR

Zomedica is slowly turning the corner with revenue growth and shrinking losses, but it's still a speculative bet on future acquisitions and product adoption.

AI Summary

Zomedica Corp. reported its Q2 2025 results, showing a net loss of $3.5 million for the three months ended June 30, 2025, a decrease from a net loss of $4.2 million in the prior-year period. Revenue for the quarter was $5.1 million, an increase of 15.9% compared to $4.4 million in Q2 2024, driven by strong sales of its TRUFORMA and PulseVet products. The company's strategic outlook includes continued investment in research and development, with R&D expenses increasing by 10% to $1.1 million in Q2 2025. Zomedica is actively managing its cash position, ending the quarter with $105.2 million in cash and cash equivalents, down from $110.5 million at the end of Q1 2025. Key business changes include the integration of the Cresilon acquisition, which is expected to contribute significantly to future revenue, with potential milestone payments tied to sales targets of $10 million, $20 million, and $30 million by December 30, 2024. Risks include intense competition in the veterinary diagnostics market and the successful integration of acquired technologies like Brisby Inc.'s SmartPetPad and IntelligentPetPad, acquired on April 4, 2023. The company aims to achieve profitability through organic growth and strategic acquisitions.

Why It Matters

Zomedica's Q2 2025 performance, with a 15.9% revenue increase and reduced net loss, signals potential for its niche in veterinary diagnostics and therapeutics. For investors, this indicates progress towards profitability, though the company remains loss-making. Employees benefit from a growing company with strategic acquisitions like Cresilon, potentially expanding product lines and market reach. Customers gain access to innovative products like TRUFORMA and PulseVet, enhancing veterinary care. In a competitive market, Zomedica's ability to grow revenue and integrate acquisitions like Brisby Inc. is crucial for long-term viability against larger players.

Risk Assessment

Risk Level: medium — The company reported a net loss of $3.5 million for Q2 2025, indicating it is not yet profitable. While revenue increased by 15.9% to $5.1 million, Zomedica faces significant competition and the successful integration of acquisitions like Cresilon, with milestone payments tied to sales targets of $10 million, $20 million, and $30 million by December 30, 2024, presents execution risk.

Analyst Insight

Investors should monitor Zomedica's progress on Cresilon integration and sales targets, as well as the continued growth of TRUFORMA and PulseVet. Consider a small, speculative position if you believe in the long-term potential of its veterinary diagnostic and therapeutic portfolio, but be aware of the ongoing losses and competitive landscape.

Financial Highlights

revenue

$5.1M

net Income

-$3.5M

cash Position

$105.2M

revenue Growth

+15.9%

Revenue Breakdown

Key Numbers

• $5.1M — Q2 2025 Revenue (Increased by 15.9% from Q2 2024)
• -$3.5M — Q2 2025 Net Loss (Reduced from -$4.2M in Q2 2024)
• 15.9% — Revenue Growth (Year-over-year increase in Q2 2025 revenue)
• $105.2M — Cash and Equivalents (As of June 30, 2025, providing liquidity)
• $1.1M — R&D Expenses (Increased by 10% in Q2 2025, showing investment)

Key Players & Entities

• Zomedica Corp. (company) — filer of the 10-Q
• Cresilon (company) — acquired company with sales milestone payments
• Brisby Inc. (company) — acquired company on April 4, 2023
• TRUFORMA (product) — key product contributing to revenue growth
• PulseVet (product) — key product contributing to revenue growth
• $3.5 million (dollar_amount) — net loss for Q2 2025
• $5.1 million (dollar_amount) — revenue for Q2 2025
• $4.4 million (dollar_amount) — revenue for Q2 2024
• $105.2 million (dollar_amount) — cash and cash equivalents at June 30, 2025
• $1.1 million (dollar_amount) — R&D expenses in Q2 2025

FAQ

Risk Factors

• Intense Competition [high — market]: Zomedica operates in the veterinary diagnostics market, which is characterized by intense competition. This competitive landscape could impact market share and pricing power for Zomedica's products.
• Integration of Acquired Technologies [medium — operational]: The successful integration of acquired technologies, such as Brisby Inc.'s SmartPetPad and IntelligentPetPad, is crucial for future growth. Any delays or inefficiencies in integration could hinder the realization of expected benefits.
• Milestone Payments for Cresilon Acquisition [medium — financial]: The Cresilon acquisition includes potential milestone payments tied to sales targets of $10 million, $20 million, and $30 million by December 30, 2024. Failure to meet these targets could result in additional financial obligations or impact the overall value proposition of the acquisition.

Industry Context

Zomedica operates within the veterinary diagnostics market, a sector experiencing growth driven by increased pet ownership and a greater focus on animal health. The market is competitive, with established players and emerging technologies vying for market share. Innovation in diagnostic tools and services is a key trend.

Regulatory Implications

As a company in the medical device and pharmaceutical space, Zomedica is subject to regulatory oversight. While this filing does not detail specific regulatory challenges, compliance with relevant health and safety regulations is paramount for product approval and market access.

What Investors Should Do

1. Monitor Cresilon acquisition performance
2. Assess R&D investment impact
3. Observe competitive positioning

Key Dates

• 2025-06-30: End of Q2 2025 — Reported $5.1 million in revenue and a net loss of $3.5 million. Company held $105.2 million in cash and cash equivalents.
• 2024-12-30: Cresilon Acquisition Milestone Targets — Sales targets of $10M, $20M, and $30M for potential milestone payments are due by this date.
• 2023-04-04: Acquisition of Brisby Inc. — Acquisition of SmartPetPad and IntelligentPetPad technologies, impacting operational integration risks.

Glossary

TRUFORMA

A diagnostic platform offered by Zomedica. (A key product driving revenue growth in Q2 2025.)

PulseVet

A product line offered by Zomedica, likely related to veterinary care. (A key product driving revenue growth in Q2 2025.)

Cresilon acquisition

A strategic acquisition by Zomedica, with potential milestone payments tied to sales performance. (Expected to contribute significantly to future revenue, but carries financial and integration risks.)

Brisby Inc.

A company whose technologies (SmartPetPad, IntelligentPetPad) were acquired by Zomedica. (Represents acquired technology that requires successful integration.)

Year-Over-Year Comparison

In Q2 2025, Zomedica reported a revenue of $5.1 million, a notable increase of 15.9% compared to the prior-year period. The net loss also improved, decreasing to $3.5 million from $4.2 million in Q2 2024, indicating progress in cost management or revenue generation efficiency. While cash reserves slightly decreased from $110.5 million at the end of Q1 2025 to $105.2 million, the company maintains a strong liquidity position. New risks related to the integration of the Cresilon acquisition and its associated milestone payments have emerged since the previous filing.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding Zomedica Corp. (ZOMDF).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR